AMGN Amgen Inc.

-0.15  -0%
Previous Close 186.47
Open 186.81
Price To book 4.29
Market Cap 135953003705
Shares 729,674,773
Volume 2,020,208
Short Ratio 3.59
Av. Daily Volume 2,507,045

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released September 7, 2017 - primary endpoint met.
sBLA filing announced July 31, 2017.
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
Phase 3 trial met primary endpoint. HR 79%.
Relapsed Multiple Myeloma
sBLA approval announced June 29, 2017.
Vectibix (Panitumumab)
Wild-Type RAS Metastatic Colorectal Cancer
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved April 15, 2015.
Chronic Heart Failure
Phase 3 cardiovascular outcomes study data released March 17, 2017 - endpoints met but down on expectations. PDUFA date under priority review December 2, 2017.
Cardiovascular disease
sBLA filing announced April 4, 2017. Acceptance of filing announced June 19, 2017 - PDUFA February 3, 2018.
Multiple Myeloma
Phase 3 commencement announced December 1, 2016. Enrollment to continue throughout 2017.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 trial initiated June 2015.
Multiple Myeloma
Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS). PDUFA date for sNDA April 30, 2018.
Relapsed Multiple Myeloma
Phase 3 trial met primary endpoint September 2016. PDUFA date May 17, 2018.
PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
Phase 3 enrolling. Estimate data 1H 2018 using data.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
BLA filing announced July 31, 2017.
ABP 980
Herceptin biosimilar
Phase 3 enrolling.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Phase 2/3 ongoing. Expected completion 2023.
CNP 520
Alzheimer’s Disease
Approved February 7, 2017.
Secondary hyperparathyroidism (SHPT)
CRL issued July 16, 2017.
EVENITY (Romosozumab)

Latest News

  1. Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA
  2. Is Amgen (AMGN) a Great Stock for Value Investors?
  3. How This Immigrant Entrepreneur Built A $5 Billion Healthcare Company
  4. We're not chasing electric utilities: Heartland Financial...
  5. Gilead Sciences: Is The Kite Deal Too Little, Too Late?
  6. FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
  7. 3 Great Income Stocks That Could Double Their Dividends
  8. FDA Approves First 'Biosimilar' for Cancer Treatment
  9. Top Research Reports for Philip Morris, Amgen & Union Pacific
  10. Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
  11. Amgen/Allergan's Avastin Biosimilar Secures FDA Approval
  12. New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes
  13. A Biosimilar Cure for Sky-High Cancer Drug Prices
  14. Biosimilar 2017 Progress Report: Stocks in Focus
  15. Amgen, Inc. : AMGN-US: Dividend Analysis : August 17th, 2017 (record date) : By the numbers : September 14, 2017
  16. Amgen and Allergan say FDA has approved biosimilar of Roche's Avastin
  17. FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
  18. U.S. FDA approves biosimilar version of cancer drug Avastin
  19. UAB makes headway with new osteoporosis drug
  20. The FDA just approved the first direct competitor to a billion-dollar cancer drug